

- preliminary efficacy data. Hepatitis C Intervention Therapy Group. *Clin Pharmacol Ther* 2000; 68: 556.
3. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than Peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. *Gastroenterology* 2010; 138: 116.
 4. Ikegami T, Toshima T, Takeishi K, et al. Bloodless splenectomy during liver transplantation for terminal liver diseases with portal hypertension. *J Am Coll Surg* 2009; 208: e1.
 5. Ikegami T, Taketomi A, Soejima Y, et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. *Transplantation* 2009; 88: 303.
 6. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. *Gastroenterology* 2012; 142: 1132.
 7. Sporea I, Danila M, Sirlu R, et al. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. *J Gastrointest Liver Dis* 2006; 15: 125.
 8. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. *J Antimicrob Chemother* 2004; 53: 15.
 9. Escudero A, Rodríguez F, Serra MA, et al. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. *J Gastroenterol Hepatol* 2008; 23: 861.
 10. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. *Hepatology* 2009; 49: 22.
 11. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. *Liver Transpl* 2006; 12: 1067.
 12. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. *Am J Transplant* 2006; 6: 2348.
 13. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. *Liver Transpl* 2007; 13: 1100.
 14. Dinges S, Morard J, Heim M, et al. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. *Transpl Infect Dis* 2009; 11: 33.
 15. Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. *Am J Transplant* 2006; 6: 1586.
 16. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. *Ann Intern Med* 2009; 150: 528.
 17. Herrine SK, Brown RS Jr, Bernstein DE, et al. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. *Dig Dis Sci* 2005; 50: 719.
 18. Boo I, Fischer AE, Johnson D, et al. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)interferon/ribavirin. *J Clin Virol* 2007; 39: 288.
 19. Selzner N, Guindi M, Renner EL, et al. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. *J Hepatol* 2011; 55: 207.
 20. Takeishi K, Shirabe K, Toshima T, et al. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case. *Surg Today* 2011; 41: 1016.

ERRATUM

Anonymity and Live-Donor Transplantation: An ELPAT View: Erratum

In the February 27, 2013 issue of *Transplantation* in the article by Mamode et al, "Anonymity and Live-Donor Transplantation: An ELPAT View" the author Frank Dor should have been listed as Frank J.M.F. Dor.

REFERENCE

Mamode N, Lennerling A, Citterio F, et al. Anonymity and live-donor transplantation: an ELPAT view. *Transplantation*. 2013; 95: 536.

厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業
がん化学療法及び免疫抑制療法中の
B型肝炎ウイルス再活性化予防対策法の確立を目指した
ウイルス要因と宿主要因の包括的研究
(H24 -肝炎-一般-004)
平成25年度 総括・分担研究報告書

発行日 平成26(2014)年3月

発行者 「がん化学療法及び免疫抑制療法中のB型肝炎ウイルス再活性化
予防対策法の確立を目指したウイルス要因と宿主要因の包括的研究」
研究代表者 溝上 雅史

発行所 国立国際医療研究センター 肝炎・免疫研究センター
〒272-8516 千葉県市川市国府台1-7-1
TEL：047-372-3501 FAX：047-375-4766

